A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

846279 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-15

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to learn how effective is PCV20 to help stop adults from getting pneumonia. Pneumonia is an infection of the lungs that can be caused by germs like bacteria, virus, or fungi. This study uses existing healthcare information. No participants will be actively enrolled. The information of participants will be taken from Kaiser Permanente Southern California's (KPSC) electronic health records (EHR).

We will look at the EHR information for adults who meet the following points:

* 18 years of age or older and a KPSC member as of 01 July 2022.
* have been a KPSC member for at least one year before 01 July 2022.
* have not received PCV15.
* have had pneumonia or lower respiratory tract infection within 30 days of 01 July 2022.

The study will begin from 01 July 2022 and will be followed through 30 June 2025. At the end of the follow-up period, the study will compare the number of pneumonia cases among people who receive PCV20 who do not receive it.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older

NCT06782282

Community-Acquired Pneumonia (CAP)

ACTIVE_NOT_RECRUITING

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

NCT06182124

Pneumococcal Disease

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

NCT05452941

Pneumonia

RECRUITING

Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease

NCT00457977

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE3

Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007)

NCT00560950

Pneumococcal Infection

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adults ≥18-64 years old with medical conditions and behavioral risk factors

Receipt of PCV20

Intervention Type BIOLOGICAL

The main exposure of interest will be receipt of PCV20.

Adults ≥65 years old

Receipt of PCV20

Intervention Type BIOLOGICAL

The main exposure of interest will be receipt of PCV20.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Receipt of PCV20

The main exposure of interest will be receipt of PCV20.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged ≥18 years at cohort entry;
2. Continuous enrollment, allowing for 45-day administrative gap, for at least one year prior to cohort entry;
3. At least one outpatient visit in the prior to cohort entry.

Exclusion Criteria

1. PCV15 received any time before or after the cohort entry date;
2. a diagnosis code in the electronic health record (EHR) for pneumonia or lower respiratory tract infection (LRTI) was made within 30 days prior to cohort entry;
3. Kaiser Permanente Southern California (KPSC) members with zero outpatient visits.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No